RESEARCH ARTICLE

Risk of venous occlusion after lead laser extraction preventing future lead implantation

Sameer Al-Maisary*, Jamila Kremer, Gabrielle Romano, Matthias Karck and Raffaele De Simone

Abstract

Background: Lead laser extraction is a well-established method for removing unwanted leads with low morbidity and mortality.

Objective: In this observational study, we documented our experience with venous occlusion after lead laser extraction.

Methods: Retrospective data of patients who underwent lead laser extraction between May 2010 and August 2018 was analyzed. Two subgroups of patients were identified. First group represented patients after lead laser extraction who suffered postoperative venous occlusion. Second group represents patients after lead laser extraction, who has documented patent venous access after lead laser extraction.

Results: 219 patients underwent percutaneous laser lead extraction. The mean age of patients was 65 ± 14 years. Of these patients, 74% were male. The Most common indication for extraction was Nonfunctional lead (45.2%, n = 99) followed by pocket infection with 33.8% and endocarditis (17.3%). A total number of 447 leads underwent laser extraction. In 7.8% of the patients, lead extraction was partially successful and lead extraction was not successful in only 2.3% of the patients. Only 13 patients developed a documented venous occlusion postoperatively and 26 patients has documented absence of venous occlusion, of whom 17 were under oral anticoagulation.

Conclusion: Lead laser extraction may lead to venous occlusion, which is mostly asymptomatic but it prevents future lead implantation. The use of oral anticoagulant may prevent postoperative venous occlusion.

Keywords: Lead laser extraction, Venous occlusion, Cardiac implantable electronic devices, Thrombosis, Anticoagulation

Background

The implantation of Cardiac implantable electronic devices (CIED) has increased in the last decades due the benefit of increasing survival and improving the quality of life in patients with cardiac rhythm disorders. This wide spread use is also associated with an increase in post-implantation complication of which is infection and dysfunction the most prominent ones due to its effect on therapy strategies and the life expectancy of the affected patients due to the significant increase in morbidity and mortality [1, 2]. The infection rate of CEIDs ranges between 1 and 7%. On the other hand, the rate of dysfunctional leads reaches 7% [3–7]. Device removal is the gold standard for treating CIED infection because conservative therapies usually fail [8, 9]. Extraction of infected or dysfunctional leads was performed using different strategies, starting with simple traction or continuous traction to using polymer or metal sheath systems with or without locking stylets. More recently, new devices were introduced using laser or radiofrequency. These are cost and time-consuming procedures needing highly trained and experienced operators. The percutaneous lead extraction

*Correspondence: yemendoctor@yahoo.com
Department of Cardiac Surgery, Heidelberg University Hospital, INF 420, 69120 Heidelberg, Germany

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
is also accompanied with serious life-threatening complications. The evidence of venous injury during lead laser extraction was documented and until now and no serious consequences were presented [10]. We report our experience in CEID extraction using the 80 Hz high frequency laser sheaths to evaluate its safety and efficacy and the risk of venous thrombosis following extraction.

Materials and methods
This is a retrospective observational study of consecutive patients who underwent laser-assisted lead extraction (using GlideLight laser sheath, Spectranetics Corporation, Colorado Springs, USA) between May 2010 and August 2018. The indications for lead extraction varied between pocket infection, device-related endocarditis, pain, and abandoned leads. Patients were referred from external hospitals or from our electrophysiological outpatient clinic. Indications for lead extraction were Pocket infection, Device-related endocarditis, Pain, abandoned or non-functioning leads and blood vessel obstruction. Pocket infection was defined as redness with or without purulent discharge from the device pocket or device erosion which may be accompanied by pain. Device-related endocarditis was defined as persistent bacteremia or sepsis in the absence of another identifiable source or the presence of vegetations on the leads or the valves. Pain related to CEID or Leads was considered also as an indication for extraction. Extraction of abandoned or non-functioning leads is performed if they produce obstruction to a blood vessel or if a new lead implantation will increase the burden of the total lead number. The use of Laser Sheath was indicated if the removal of the leads under simple traction is not successful. All procedures were performed under general anesthesia with continuous arterial blood pressure monitoring. Under fluoroscopic guidance, the lead extraction starts by inserting a lead locking stylet into the inner coil lumen then a suture is tied around the insulation and the locking stylet. After that, the laser sheath (Glide Light 80 Hz, 14 or 16 French) was advanced over the lead until the locking stylet emerges from the other side of the laser sheath. Laser is then applied while gradually advancing the sheath over the lead under traction until the lead is freed. If all leads are removed, the procedure was considered successful. Transesophageal echocardiography was used to monitor the procedure. If the has no infection, device reimplantation was performed from the same side after advancing a guide wire through laser sheath. In patients with local or systemic infection, no device would be implanted unless the patient is pace-maker dependent. In this case an epicardial pace maker lead is implanted though a an inferior pericardiotomy as described by Al-Maisary et al. [11] and after remission of infection, the patient would be re-evaluated for dual-chamber pace-maker implantation. An electronic database of all patients was retrospectively analyzed to obtain the needed information. The collected data includes patients’ characteristics, indications for lead extraction, type of lead and age of lead, details of procedure, intra- and postoperative complications, in-Hospital mortality up to 30 days and pre- and postoperative medications. Removal of all leads was considered as procedural success. Removal of some leads was considered as partial success. Procedural failure was defined as the inability to remove any lead. Two subgroups were identified for investigating venous occlusion. The first group represents the venous occlusion group. Venous occlusion was diagnosed if a patient shows clinical symptoms of venous thrombosis of arm veins confirmed whether using duplex ultrasound, Phlebography or Computer tomography angiography. Also, patients who underwent phlebography or duplex ultrasound examination, after laser lead extraction, for preoperative evaluation prior to the implantation of pacemaker leads with newly developed venous occlusion, were included. The second group (control group) included each patient who underwent phlebography, duplex ultrasound showing patent vessels after laser extraction or who successfully received new leads or indwelling catheters in the same side of laser extraction and differences between these two groups were investigated. Data analysis for Demographic Data, medical history, and lead-related characteristics were presented as frequency (%) for categorical variables and as mean plus or minus standard deviation for normally distributed continuous variables. The study protocol was approved by the institutional research ethics board at Heidelberg University.

Results
From May 1, 2010 to Mars 25, 2018 a total of 219 patients underwent percutaneous laser lead extraction in our center. Patient characteristics can be seen in Table 1.

The mean age of patients was 65±14 years. Of these patients, 163 were male (74.4%). The body mass index was 27.6±10.5 and 31.9% had diabetes mellitus. The ejection fraction was 42.05±14.5% and only 10 (4.6%) patients has NYHA class IV. Coronary heart disease was seen in 106 (48.4%) of patients and 85.4% of patient has arterial hypertension. Only 12.8% presented with renal insufficiency. Most of the patients (73.97%) had an ICD. The indications for lead extraction in this study are presented in Table 2.

The Most common indication for extraction was Non-functional lead (45.2%, n = 99) followed by pocket infection with 33.8% and endocarditis (17.3%). Sepsis or bacteremia related lead or device implantation was present in 11.4% of patients. Functional abandoned leads
were an indication for lead extraction in 4.1% of patients. Only 1.82% of patients had venous stasis or occlusion and 2 patients asked for device remove due to chronic pain. A total number of 447 leads were underwent laser extraction with a mean time from implantation of 100.40 ± 64.23 months. Single coil ventricular leads were the most frequently encountered leads (28.63%) followed by atrial leads and dual coil leads. Coronary Sinus leads were the least frequently removed leads (6.7%). Most of the Leads (91.5%) were extracted successfully. For patients, the percentage of successful removal of all leads was 90%, for partial removal 7.8% and only in 2.3% of the patients had no leads removed with no statistical significance. Lead Demographics are shown in Table 3.

Only one patient suffered from superior vena cava tier requiring open surgery. One patient died due to pulmonary embolism. Thirteen patients have developed a documented venous occlusion postoperatively and 26 patients has documented absence of venous occlusion. A total of 30 leads was extracted (2.3 lead per patient) in the venous occlusion group and 50 (1.9 lead per patient) in the control group. Most of the extracted leads were single coil ventricular leads (28.6%) followed by atrial leads (27.3%). No significant difference was observed between the groups regarding the lead demographics and the outcome of lead extraction (Table 4).

As seen in Tables 5 and 6, the patients had different anticoagulation regime. In the venous occlusion group, only one patient was under oral anticoagulation (Phenprocoumon) and 3 patients presented with symptomatic (pain and swelling) venous occlusion and in the control group. 14 patients were under Phenprocoumon, 2 patients were under Rivaroxaban, 1 patient was under Apixaban. we compared the two groups using Fisher’s exact test in regard to anticoagulation which led to a significant difference (p value = 0.047).

Discussion
By expanding the indications for CIED implantations there is an increase in associated complications. The introduction of the Laser lead extraction system has solved some of these complications and therefore making lead removal a simpler procedure. Recently, laser lead extraction became the standard of care for lead extraction with good results [12].

### Table 1 Demographics

|                    | Total | Venous occlusion group | Control group |
|--------------------|-------|------------------------|---------------|
| Patients n         | 219   | 13                     | 26            |
| Age (years)        | 65 ± 14 | 57 ± 17                 | 61 ± 18       |
| Sex, % male (n = 163) | 74.4  | 4.5 (10)               | 6.8 (15)      |
| Body mass index    | 27.6 ± 10.5 | 25.0 ± 5.6             | 26.8 ± 4.4    |
| Diabetes mellitus, % (n) | 31.9% (70) | 1.36 (3)              | 3.65 (8)      |
| EF, %              | 42.05 ± 14.5 | 40.8 ± 16.0            | 34.9 ± 10.1   |
| NYHA functional class III | 62 (28.3%) | 1.5 ± 0.8              | 2.1 ± 0.9     |
| Coronary artery disease | 106 (48.4%) | 4 (1.8%)                | 14 (6.4%)    |
| Arterial hypertension | 187 (85.4%) | 11 (5.0%)              | 24 (10.9%)  |
| Renal insufficiency | 28 (12.8%) | 0                      | 5 (2.2%)     |
| ICD                | 162 (73.97%) | 10 (4.5%)              | 22 (10.0%) |

ICD, implantable cardioverter-defibrillator

### Table 2 Indications for lead extraction

|                    | Total | Venous occlusion group | Control group |
|--------------------|-------|------------------------|---------------|
| Pocket infection   | 74 (33.8%) | 2 (0.9%)              | 6 (2.7%)      |
| Endocarditis       | 38 (17.3%) | 1 (0.4%)               | 4 (1.8%)      |
| Bacteremia or Sepsis | 25 (11.4%) | 1 (0.4%)              | 3 (1.3%)     |
| Functional abandoned lead | 9 (4.1%) | 0                     | 2 (0.9%)     |
| Nonfunctional lead | 99 (45.2%) | 9 (4.1%)              | 17 (7.7%)    |
| Pain at device or insertion site | 2 (0.91%) | 1 (0.4%)               | 0             |
| Venous stasis or occlusion | 4 (1.82%) | 0                     | 0             |

### Table 3 Lead demographics

|                    | Total | Venous occlusion group | Control group |
|--------------------|-------|------------------------|---------------|
| Number of treated leads | 447   | 30                     | 50            |
| Mean time from implantation, months | 100.40 ± 64.23 | 87.7 ± 43.9          | 75.2 ± 48.2   |
| Lead type, n (% within the group) |       |                        |               |
| Atria lead          | 122 (27.29%) | 8 (26.6%)             | 11 (22.0%)    |
| Ventricular pacemaker lead | 101 (22.59%) | 6 (20.6%)        | 8 (16.0%)     |
| Coronary sinus lead | 30 (6.71%)   | 4 (13.3%)            | 5 (10.0%)     |
| Single coil lead    | 128 (28.63%) | 7 (23.3%)             | 20 (40.0%)    |
| Dual coil lead      | 66 (14.76%)  | 5 (16.7%)            | 6 (12.0%)     |
Present adhesion and fibrosis in the venous system of long-lying leads can bear new challenges and complications which have not been described before.

The use of lead laser extraction sheath can cause vessel or organ perforation, vessel injury and embolism of tissue fragment. Any of these complications entail further adverse events such as massive bleeding, cardiac or vascular avulsion or tears, arrhythmias, heart failure or even death [13, 14]. Autopsy findings performed on 78 deceased patients with a CIED found tissue cuffs in 71% of atrial leads and 87% of ventricular leads. The degree of fibrosis depends on the dwell time of the hardware and younger patient age [15]. In our patient cohort, severe complications associated with lead extractions requiring emergency surgery were < 1%.

In our study population, we faced difficulties implanting new CIED in patients who underwent previous laser lead extraction due to occlusion of the venous access. In contrast, patients with oral anticoagulation showed less occlusions after laser extraction. Tarakji et al. described the effect of laser lead extraction on the structures surrounding the extracted leads. They described how removed leads contained remnants of vascular, atrial and ventricular tissue. It can be concluded that laser sheaths create abrasive surfaces in the vascular system after laser lead extraction. These surfaces are exposed to blood flow and thrombus formation is more likely as a natural response to vessel injury.

It is likely that many patients had occluded venous systems prior to extraction. The lead extraction may have temporarily opened a channel in the subclavian vein thus causing collapse of chronic collateral systems thus when the laser created channel subsequently occluded, patients manifest acute vein occlusion. The theory has until now no studies to support it.

This limited study aims to open an eye on a possible complication which may affect the lives of many patients, especially patients who are dependent on CIED in their life. Many CIED patients are anticoagulated due to various reasons, this limits the complication of venous occlusion after laser lead extraction to a smaller group of non-anticoagulated patients. More detailed studies with a larger patient volume are necessary to further investigate the vascular damage after laser lead extraction. A lot of patients are asymptomatic after venous thrombosis, which may play a leading role in concealing such a complication. Luckily the administration of anticoagulants

Table 4 Outcome of laser Lead extraction

| Outcome per lead | Total | Venous occlusion group | Control group |
|------------------|-------|------------------------|---------------|
| Success, n (%)   | 409 (91.5) | 24 (80%) | 48 (96%) |
| Failure, n (%)   | 38 (8.5) | 6 (20%) | 2 (4%) |

| Outcome per patient | Complete Success, n (%) | Partial success, n (%) | Failure, n (%) |
|---------------------|-------------------------|------------------------|--------------|
|                     | 197 (99.0) | 11 (84%) | 25 (96.1%) |
|                     | 17 (7.8) | 2 (15.4%) | 1 (3.9%) |
|                     | 5 (2.3) | 0 | 0 |

Table 5 Characteristics of the venous occlusion group

| Patient | Operation                        | Place of occlusion | Evidence of occlusion | Anticoagulation         |
|---------|----------------------------------|--------------------|-----------------------|-------------------------|
| 1       | Bilateral Lead laser extraction  | Bilateral subclavian veins, brachiocephalic vein and Superior vena cava | Phlebography | Aspirin 100 mg OD |
| 2       | Bilateral Lead laser extraction  | Bilateral subclavian veins | Phlebography | None |
| 3       | Left-sided lead laser extraction | Subtotal left axillary vein | Duplex Sonography | Aspirin 100 mg OD |
| 4       | Left-sided lead laser extraction | Left subclavian vein | Duplex Sonography | None |
| 5       | Left-sided lead laser extraction | Left subclavian vein | Phlebography | None |
| 6       | Left-sided lead laser extraction | Left subclavian vein | Phlebography | None |
| 7       | Left-sided lead laser extraction | Left subclavian and internal jugular veins | Phlebography | None |
| 8       | Left-sided lead laser extraction | Left subclavian vein | Phlebography | Phenprocoumon |
| 9       | Left-sided lead laser extraction | Left subclavian vein | Duplex Sonography and CT-Scan angiography | None |
| 10      | Left-sided lead laser extraction | Left subclavian vein | Phlebography | None |
| 11      | Left-sided lead laser extraction | Left subclavian vein | Phlebography | None |
| 12      | Left-sided lead laser extraction | Left subclavian vein | Guide wire could not be advanced through the vein | None |
| 13      | Left-sided lead laser extraction | Left subclavian vein | Phlebography | Aspirin 100 mg OD |
may prevent postoperative thrombosis. However, we need more evidence through a randomized study as our study is limited to a very small group of patients.

**Conclusion**

Laser lead extraction may cause venous occlusion, which can prevent future lead implantation but randomised trials would be needed.

**Abbreviations**

CIED: Cardiac implantable electronic devices; NYHA: New York Heart Association; ICD: Implantable cardioverter defibrillator.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

SM: contributed to the conception, the design of the work, the acquisition, analysis, and interpretation of data and also wrote the manuscript. JK contributed to the conception and the design of the work. GR contributed to the design of the work, the acquisition, analysis, and interpretation of data. MK contributed to the design of the work. RDS contributed to the conception and the design of the work. All authors read and approved the final manuscript.

**Funding**

Open Access funding enabled and organized by Projekt DEAL. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Availability of data and materials**

The datasets generated and/or analysed during the current study are not publicly available due to native language of the data but are available from the corresponding author on reasonable request and should be translated at first.

**Declarations**

**Ethics approval and consent to participate**

The study protocol was approved by the institutional research ethics board at Heidelberg University.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 2 February 2021  **Accepted:** 24 October 2021  
**Published online:** 30 October 2021

---

**Table 6** Characteristics of the control group

| Patient | Operation              | Evidence of patency | Anticoagulation                  |
|---------|------------------------|---------------------|----------------------------------|
| 1       | Left-sided lead laser extraction | Phlebography        | Rivaroxaban 15 mg OD             |
| 2       | Left-sided lead laser extraction | Duplex sonography   | Phenprocoumon                    |
| 3       | Left-sided lead laser extraction | Duplex sonography   | Phenprocoumon                    |
| 4       | Left-sided lead laser extraction | Phlebography        | Aspirin 100 mg OD                |
| 5       | Right-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 6       | Left-sided lead laser extraction | Phlebography        | Rivaroxaban 20 mg                |
| 7       | Left-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 8       | Left-sided lead laser extraction | Phlebography        | Aspirin 100 mg OD                |
| 9       | Left-sided lead laser extraction | Duplex sonography   | Phenprocoumon Apixaban 5 mg OD   |
| 10      | Left-sided lead laser extraction | Duplex sonography   | Phenprocoumon                    |
| 11      | Left-sided lead laser extraction | Phlebography        | Aspirin 100 mg                   |
| 12      | Right-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 13      | Left-sided lead laser extraction | Duplex sonography   | Clopidogrel 75 mg                |
| 14      | Left-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 15      | Left-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 16      | Left-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 17      | Left-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 18      | Left-sided lead laser extraction | Phlebography        | Aspirin 100 mg OD and Enoxaparin 60 mg |
| 19      | Left-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 20      | Left-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 21      | Left-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 22      | Right-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 23      | Left-sided lead laser extraction | Phlebography        | None                             |
| 24      | Left-sided lead laser extraction | Phlebography        | Phenprocoumon                    |
| 25      | Left-sided lead laser extraction | Phlebography        | None                             |
| 26      | Left-sided lead laser extraction | Phlebography        | None                             |
References

1. Klug D, Lacroix D, Savoye C, et al. Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Circulation. 1997;95:2098–107.

2. Goldberger Z, Lampert R. Implantable cardioverter-defibrillators: expanding indications and technologies. JAMA. 2006;295:809–18.

3. Love CJ, Wilkoff BL, Byrd CL, et al. Recommendations for extraction of chronically implanted transvenous pacing and defibrillator leads: indications, facilities, training. North American Society of Pacing and electrophysiology lead extraction conference faculty. Pacing Clin Electrophysiol. 2000;23:544–51.

4. Byrd CL, Wilkoff BL, Love CJ, Sellers TD, Reiser C. Clinical study of the laser sheath for lead extraction: the total experience in the United States. Pacing Clin Electrophysiol. 2002;25:804–8.

5. Sohail MR, Uslan DZ, Khan AH, et al. Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. Mayo Clin Proc. 2008;83:46–53.

6. Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol. 2007;49:1851–9.

7. Silvetti MS, Drago F. Outcome of young patients with abandoned, non-functional endocardial leads. Pacing Clin Electrophysiol. 2008;31:473–9.

8. Vogt PR, Sagdic K, Lachat M, et al. Surgical management of infected permanent transvenous pacemaker systems: ten year experience. J Card Surg. 1996;11:180–6.

9. Lai KK, Fontecchio SA. Infections associated with implantable cardioverter defibrillators placed transvenously and via thoracotomies: epidemiology, infection control, and management. Clin Infect Dis. 1998;27:265–9.

10. Tarakji KG, et al. Unrecognized venous injuries after cardiac implantable electronic device transvenous lead extraction. Heart Rhythm. 2018;15(3):318–25.

11. Al-Maisary SSA. Epicardial pacemaker as a bridge for pacemaker-dependent patients undergoing explantation of infected cardiac implantable electronic devices. J Card Surg. 2019;34(6):424–7.

12. Wilkoff BL, Love CJ, Byrd CL, Bongjorni MG, Carrillo RG, Crossley GH III, et al. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). Heart Rhythm. 2009;6:1085–104.

13. Bongjorni MG, Kennegger C, Butter C, et al. The European Lead Extraction ConTRolled (ELECTra) study: a European Heart Rhythm Association (EHRA) registry of transvenous lead extraction outcomes. Eur Heart J. 2017;38:2995–3005.

14. Wazni O, Epstein LM, Carrillo RG, Love C, Adler SW, Riggio DW, et al. Lead extraction in the contemporary setting: the LExICon study: an observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol. 2010;55:55.579–86.

15. Novak M, Dvorak P, Kamaryt P, Sleana B, Lipoldova J. Autopsy and clinical context in deceased patients with implanted pacemakers and defibrillators: intracardiac findings near their leads and electrodes. Europace. 2009;11:1510–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.